Market Capitalization – Big Pharma - Milken Institute

More documents

Recommendations

Info

Medicines in Development For Cancer Cancer Category Number Solid Tumors 94 Lung 70 Breast 49 Colon 48 Skin 45 Prostate 44 Leukemia 40 Lymphoma 39 Cancer-related 34 Ovarian 31
Drug Target Discovery Research Ph.D. MD Lead High Throughput and Design The Translational Continuum: From Discovery to Delivery Lead Optimization Medicinal Chemistry Chemist Translational Ph.D. Physician-Scientist Target Validation The Enablers Models: Mice Primates Lead The Human Capital Physician Scientist GMP Lead Optimization Clinical Trials Clinical Delivery Manufacturing Patients G l o b a l H e a l t h Industry Clinical Investigator Clinicians
Page 2 and 3: Biopharmaceuticals: The Innovation
Page 4 and 5: Market Capitalization - Big Biotech
Page 6 and 7: Big Pharma vs. Big Biotech Market C
Page 8 and 9: U.S. Biotech Industry Summary Reven
Page 10 and 11: Nasdaq Biotech vs. Nasdaq Composite
Page 12 and 13: Mean Approval Time for New Biologic
Page 14 and 15: New Breast Cancer Drug Helps Women
Page 16 and 17: US$ Billions 35 30 25 20 15 10 5 0
Page 18 and 19: Industry R&D Predominately Higher t
Page 20 and 21: Biotech Deals and Amount Raised 199
Page 22 and 23: Total Alliance Numbers and Deal Val
Page 24 and 25: Alliance Deal Activity Top Transact
Page 26 and 27: US$ Billions 400 300 200 100 0 1994
Page 28 and 29: Up to 6.5 years Up to 6 years Up to
Page 30 and 31: Biotech Products have Better U.S. A
Page 32 and 33: Clinical and Total Cost Reductions
Page 34 and 35: Years 20 15 10 5 0 Average Effectiv
Page 36 and 37: Generics’ Share of U.S Prescripti
Page 38 and 39: Medicines in Development For Heart
Page 43 and 44: Roadblocks in Early Stage Translati
Page 45 and 46: Product Roadblocks in Mid- Stage Tr
Page 47 and 48: Market Capitalization Investing in
Page 49 and 50: Year 2001 Private Financings 180 Ov
Page 51 and 52: $ What has Changed Since 2000 Biote
Page 53 and 54: Science Then Now Science all-import
Page 55 and 56: Exits Then Now Exit via IPO Acquisi
Page 57 and 58: New Paradigms 2000 2010 High severi
Page 59 and 60: Amgen IPO Prospectus Alpha Interfer
Page 61 and 62: Between 1900 and 2000, life expecta

Market Capitalization – Big Pharma - Milken Institute

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?